SCHEMBL4246571

SCHEMBL4246571

COc1ccccc1Nc1ccccc1C(=O)O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.75
APAF1 O14727 1/20 0.75
RECQL P46063 1/20 0.75
CASP6 P55212 1/20 0.75
CACNA1B Q00975 1/20 0.75
APBA1 Q02410 1/20 0.75
MCL1 Q07820 1/20 0.75
CASP8 Q14790 1/20 0.75
AKR1C3 P42330 3/20 0.73
AKR1C2 P52895 3/20 0.73
FABP4 P15090 3/20 0.73
FABP3 P05413 2/20 0.73
FABP5 Q01469 2/20 0.73
CDC25B P30305 2/20 0.72
KMT2A Q03164 2/20 0.67
CLCN2 P51788 2/20 0.62
CHEK1 O14757 1/20 0.58
PIM1 P11309 1/20 0.58
MAPK8 P45983 1/20 0.58
CLK4 Q9HAZ1 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30638203 1.00 KDM4E (0.75) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL11648254 0.88 AKR1C3 (0.76) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL1961597 0.87 AKR1C3 (0.62) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL10935377 0.86 AKR1C3 (0.65) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL30567368 0.86 AKR1C3 (0.65) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL1720516 0.86 KDM4E (1.00) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL29441241 0.86 KDM4E (1.00) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL14376023 0.86 AKR1C3 (0.82) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL13271379 0.85 FABP3 (0.68) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL28565067 0.85 FABP4 (1.00) KDM4EAPAF1RECQLCASP6CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4921875-A Use of amino-substituted benzoic acids as remedies for diarrhea, and medicaments based on these compounds HOECHST AKTIENGESELLSCHAFT (DE) 1990-05-01 US claimed
CN-111057004-B N-o-substituted phenyl benzamide-4-methylaminoacridine compound and preparation method and application thereof 宁波大学 2023-10-31 CN disclosed
CN-111057004-A N-ortho-substituted phenyl benzamide-4-methylaminoacridine compound and preparation method and application thereof 宁波大学 2020-04-24 CN disclosed
US-20090131527-A1 NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-05-21 US disclosed
US-20070031854-A1 Novel 10,10'-substituted-9,9'-biacridilidine luminescent molecules their preparation and uses KATSILOMETES GEORGE W 2007-02-08 US disclosed
US-20020034828-A1 NOVEL 10,10'-SUBSTITUTED-9,9'-BIACRIDINE LUMINESCENT MOLECULES AND THEIR PREPARATION PIERCE CHEMICAL COMPANY 2002-03-21 US disclosed
EP-0737722-B1 New indoaniline metal complex, process for their production, and transparent recording medium and optical recording medium by use thereof JUJO PAPER CO LTD (JP) 2001-07-04 EP disclosed
EP-1026156-A2 Novel 10, 10'-substituted-9,9'-biacridine luminescent molecules and their preparation PIERCE CHEMICAL COMPANY (US) 2000-08-09 EP disclosed
US-5919928-A Phenanthridine derivatives and metal complexes thereof used for transparent recording medium or optical recording medium NIPPON PAPER INDUSTRIES, CO., LTD. (JP) 1999-07-06 US disclosed
US-5892042-A OPTICAL RECORDING MEDIA WITH ACRIDINE DYES ON TRANSPARENT SUBSTRATE NIPPON PAPER INDUSTRIES CO., LTD. (JP) 1999-04-06 US disclosed
US-5792863-A HAVING LARGE ABSORPTION IN NEAR INFRARED, REDUCED ABSORPTION IN VISIBLE RANGE NIPPON PAPER INDUSTRIES CO., LTD. (JP) 1998-08-11 US disclosed
EP-0737722-A2 New indoaniline metal complex, process for their production, and transparent recording medium and optical recording medium by use thereof NIPPON PAPER INDUSTRIES CO., LTD. (JP) 1996-10-16 EP disclosed
US-4629735-A ANTIASTHMATIC AGENTS STERLING DRUG INC. (US) 1986-12-16 US disclosed
US-4549016-A LIPOXYGENASE INHIBITORS, ANTIALLERGENS, ANTIASTHMA AGENTS STERLING DRUG INC. (US) 1985-10-22 US disclosed
US-4539429-A LIPOXYGENASE INHIBITORS, ANTIASTHMA STERLING DRUG INC. (US) 1985-09-03 US disclosed
US-4515980-A LIPOXYGENASE INHIBITORS STERLING DRUG INC. (US) 1985-05-07 US disclosed
US-4510139-A ANTYIALLERGENS; ASTHMA STERLING DRUG INC. (US) 1985-04-09 US disclosed
US-4496590-A TREATMENT OR PREVENTION OF ALLERGIC ASTHMA, ANTI-ASTHMATIC STERLING DRUG INC. (US) 1985-01-29 US disclosed
EP-0122518-A1 Phenylaminobenzenealkanols and preparation STERLING DRUG INC. (US) 1984-10-24 EP disclosed
US-4168312-A Quinolone derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1979-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131527-A1 NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME CLIC1, ASIC1, CLIC4 KDM4E 3594/4885APAF1 922/4885RECQL 3685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.